MA42623A - Inhibiteurs de la tyrosine kinase de bruton - Google Patents
Inhibiteurs de la tyrosine kinase de brutonInfo
- Publication number
- MA42623A MA42623A MA042623A MA42623A MA42623A MA 42623 A MA42623 A MA 42623A MA 042623 A MA042623 A MA 042623A MA 42623 A MA42623 A MA 42623A MA 42623 A MA42623 A MA 42623A
- Authority
- MA
- Morocco
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- bruton tyrosine
- bruton
- inhibitors
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169945P | 2015-06-02 | 2015-06-02 | |
| US201562169941P | 2015-06-02 | 2015-06-02 | |
| US201562169935P | 2015-06-02 | 2015-06-02 | |
| US201562249338P | 2015-11-01 | 2015-11-01 | |
| US201562249336P | 2015-11-01 | 2015-11-01 | |
| US201562249340P | 2015-11-01 | 2015-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42623A true MA42623A (fr) | 2018-06-20 |
Family
ID=57441893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042623A MA42623A (fr) | 2015-06-02 | 2016-06-02 | Inhibiteurs de la tyrosine kinase de bruton |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180305348A1 (fr) |
| EP (1) | EP3310776A4 (fr) |
| JP (1) | JP2018522823A (fr) |
| KR (1) | KR20180021740A (fr) |
| CN (1) | CN107709315A (fr) |
| AU (2) | AU2016270907B2 (fr) |
| BR (1) | BR112017025986A2 (fr) |
| CA (1) | CA2987054A1 (fr) |
| IL (1) | IL255831A (fr) |
| MA (1) | MA42623A (fr) |
| MX (1) | MX2017015574A (fr) |
| RU (1) | RU2017145650A (fr) |
| SG (1) | SG10201911523YA (fr) |
| WO (1) | WO2016196776A2 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3046578A1 (fr) * | 2016-12-21 | 2018-06-28 | Acerta Pharma B.V. | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton |
| KR101956815B1 (ko) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| KR102797697B1 (ko) | 2018-05-25 | 2025-04-22 | 에이2에이 파마수티칼스, 잉크. | 신종 항암제 후보로서, 매우 강력한 tacc3 억제제 |
| BR112021007115A2 (pt) | 2018-10-15 | 2021-07-20 | Nurix Therapeutics, Inc. | compostos bifuncionais para dedradação de btk por meio da via de proteossoma de ubiquitina |
| DK3870579T3 (da) | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibitorer og anvendelser deraf |
| WO2020167518A1 (fr) * | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| MX2021012285A (es) | 2019-04-09 | 2021-12-15 | Nurix Therapeutics Inc | Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico. |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| KR20220068227A (ko) | 2019-09-24 | 2022-05-25 | 누릭스 테라퓨틱스 인코포레이티드 | 입양 세포 요법에 사용하기 위한 cbl 억제제 및 조성물 |
| CA3159348A1 (fr) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase |
| CA3160713A1 (fr) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Composes bifonctionnels pour la degradation de la btk par l'intermediaire de la voie de l'ubiquitine-proteosome |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| CA3179395A1 (fr) * | 2020-06-01 | 2021-12-09 | Yuli Xie | Nouveau compose de pyrazine |
| WO2022071772A1 (fr) * | 2020-09-29 | 2022-04-07 | (주)메디톡스 | Inhibiteur de protéine kinase et son utilisation |
| AU2022254104A1 (en) | 2021-04-08 | 2023-10-26 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds |
| EP4323351A4 (fr) * | 2021-04-12 | 2025-07-30 | A2A Pharmaceuticals Inc | Compositions et méthodes de traitement du cancer |
| IL309427A (en) * | 2021-07-01 | 2024-02-01 | Hangzhou Healzen Therapeutics Co Ltd | TYROSINE KINASE AND MUTANT DEGRADER, Broughton's composition and application |
| KR20240090898A (ko) | 2021-10-26 | 2024-06-21 | 누릭스 테라퓨틱스 인코포레이티드 | 암을 치료 및 예방하고 btk를 분해하기 위한 피페리디닐피라진-카복스아미드 화합물 |
| WO2023088477A1 (fr) * | 2021-11-22 | 2023-05-25 | 杭州和正医药有限公司 | Composé multifonctionnel capable de dégrader la kinase btk, composition et utilisation |
| JP2025509965A (ja) | 2022-03-24 | 2025-04-11 | エーツーエー ファーマシューティカルズ インコーポレーテッド | がんを治療するための組成物及び方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797706B1 (en) * | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| US9145414B2 (en) * | 2011-09-30 | 2015-09-29 | Taiho Pharmaceutical Co., Ltd. | 1,2,4-triazine-6-carboxamide derivative |
| EP2763976B1 (fr) * | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide |
| SG11201402570QA (en) * | 2011-11-23 | 2014-06-27 | Portola Pharm Inc | Pyrazine kinase inhibitors |
| WO2013104573A1 (fr) * | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Composés de pyridazinamide et leur utilisation en tant qu'inhibiteurs de syk |
| TWI532727B (zh) * | 2012-01-17 | 2016-05-11 | 安斯泰來製藥股份有限公司 | 吡羧醯胺化合物 |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| US20140113931A1 (en) * | 2012-06-22 | 2014-04-24 | Portola Pharmaceuticals, Inc. | Substituted picolinamide kinase inhibitors |
| EP2964647A1 (fr) * | 2013-03-05 | 2016-01-13 | F. Hoffmann-La Roche AG | Inhibiteurs de tyrosine kinase de bruton |
| WO2014153280A1 (fr) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant du 2-pyridyl carboxamide |
| WO2015039613A1 (fr) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | Composé inhibant les activités kinase de btk et/ou jak3 |
| JP6345786B2 (ja) * | 2013-12-05 | 2018-06-20 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼの阻害剤 |
-
2016
- 2016-06-02 EP EP16804424.6A patent/EP3310776A4/fr not_active Withdrawn
- 2016-06-02 MX MX2017015574A patent/MX2017015574A/es unknown
- 2016-06-02 CA CA2987054A patent/CA2987054A1/fr not_active Abandoned
- 2016-06-02 CN CN201680035113.2A patent/CN107709315A/zh active Pending
- 2016-06-02 MA MA042623A patent/MA42623A/fr unknown
- 2016-06-02 WO PCT/US2016/035489 patent/WO2016196776A2/fr not_active Ceased
- 2016-06-02 BR BR112017025986A patent/BR112017025986A2/pt not_active IP Right Cessation
- 2016-06-02 KR KR1020177037849A patent/KR20180021740A/ko not_active Withdrawn
- 2016-06-02 JP JP2017560655A patent/JP2018522823A/ja active Pending
- 2016-06-02 RU RU2017145650A patent/RU2017145650A/ru not_active Application Discontinuation
- 2016-06-02 SG SG10201911523YA patent/SG10201911523YA/en unknown
- 2016-06-02 US US15/579,142 patent/US20180305348A1/en not_active Abandoned
- 2016-06-02 AU AU2016270907A patent/AU2016270907B2/en not_active Ceased
-
2017
- 2017-11-21 IL IL255831A patent/IL255831A/en unknown
-
2019
- 2019-07-17 US US16/514,544 patent/US20210070748A1/en not_active Abandoned
-
2020
- 2020-12-11 AU AU2020286332A patent/AU2020286332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL255831A (en) | 2018-01-31 |
| JP2018522823A (ja) | 2018-08-16 |
| WO2016196776A3 (fr) | 2017-01-05 |
| EP3310776A4 (fr) | 2019-01-16 |
| AU2016270907B2 (en) | 2020-09-17 |
| EP3310776A2 (fr) | 2018-04-25 |
| WO2016196776A2 (fr) | 2016-12-08 |
| KR20180021740A (ko) | 2018-03-05 |
| CN107709315A (zh) | 2018-02-16 |
| AU2020286332A1 (en) | 2021-01-21 |
| RU2017145650A3 (fr) | 2019-11-22 |
| AU2016270907A1 (en) | 2017-12-07 |
| BR112017025986A2 (pt) | 2018-08-14 |
| US20210070748A1 (en) | 2021-03-11 |
| SG10201911523YA (en) | 2020-02-27 |
| RU2017145650A (ru) | 2019-07-15 |
| CA2987054A1 (fr) | 2016-12-08 |
| MX2017015574A (es) | 2018-08-09 |
| US20180305348A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | tyrosine kinase inhibitors | |
| MA42623A (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| EP3414234A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA43162A (fr) | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| EP3347018A4 (fr) | Inhibiteurs de kinases cycline-dépendantes | |
| EP3405192A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3283077A4 (fr) | Inhibiteurs de bromodomaine | |
| EP3247692A4 (fr) | Inhibiteurs de trka kinase | |
| DK3365334T3 (da) | Benzolactamforbindelser som proteinkinaseinhibitorer | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| HUE050842T2 (hu) | Janus-kináz inhibitor | |
| BR112017002232A2 (pt) | combinações de inibidor de tirosina quinase de bruton e usos das mesmas | |
| MA44474A (fr) | Nouveaux inhibiteurs de la ferroportine | |
| EP3442972A4 (fr) | Inhibiteurs de bromodomaine | |
| DK3290418T3 (da) | Janus Kinase (JAK)-hæmmere | |
| EP3313828A4 (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| BR112017020743A2 (pt) | cocristais de um inibidor da tirosina cinase de bruton. | |
| LT3728207T (lt) | Chinazolinonai kaip parp14 inhibitoriai | |
| BR112017015206A2 (pt) | síntese de um inibidor de tirosina quinase de bruton | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| EP3349754A4 (fr) | Inhibiteurs de pcna | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases |